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Elongation factor-1 (EF-1) delta is a subunit of EF-1, which is a protein complex that participates in the elongation step of mRNA
translation and has recently been considered to correlate with oncogenic transformation. However, there has been no information
regarding the clinical significance of EF-1 delta mRNA expression in malignant tumours, including oesophageal carcinoma. Thus, we
quantitated the expression of EF-1 delta in malignant and benign oesophageal tissues and associated these levels with clinicopathologic
parameters of oesophageal carcinoma. Paired oesophageal tissue samples from cancerous and corresponding noncancerous parts were
obtained from 52 patients who underwent curative oesophagectomy. Quantitative analyses of EF-1 delta expression were performed
using real-time quantitative reverse transcription–polymerase chain reaction. Elongation factor-1 delta mRNA overexpression in
cancerous tissues compared to normal counterparts was observed in 38 of 52 (73%) patients. The mean expression level of EF-1 delta
mRNA in cancerous tissues was significantly higher than that in noncancerous tissues (Po0.01). A higher expression of EF-1 delta was
significantly correlated with lymph node metastases (Po0.05) and advanced stages (Po0.05). Furthermore, the cause-specific survival
of patients with a higher expression of EF-1 delta was significantly poorer than those with a lower expression (5-year cause-specific
survival rates; 23 and 54%, respectively, Po0.05). The results of this study indicated that EF-1 delta mRNA expression was significantly
higher in cancerous compared to noncancerous oesophageal tissues, and a higher expression of EF-1 delta mRNA was correlated with
lymph node metastases, advanced disease stages and poorer prognosis for patients with oesophageal carcinoma.
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Elongation factor-1 (EF-1) delta is a part of the EF-1 protein
complex that mediates the elongation step of protein synthesis by
transferring aminoacyl-t RNA to 80S ribosomes fuelled by the
hydrolysis of guanosine 50-triphosphate (GTP) (Riis et al, 1990;
Proud, 1994). Elongation factor-1 is composed of four subunits:
alpha, beta, gamma and delta. Elongation factor-1 comprises the
following distinct functional domains: a nucleotide-binding
domain (EF-1 alpha) and a nucleotide-exchange protein complex
(EF-1 beta/gamma). Elongation factor-1 delta also possesses a
nucleotide-exchange activity and interacts with EF-1 alpha and EF-
1 beta/gamma. The N-terminal domain of EF-1 delta contains the
six-residue leucine-zipper motif typically seen in transcription
factors, the function of which is not known (Sanders et al, 1993).
Considerable evidence suggests that translation factor activity
plays an important role in regulating cellular growth, and several
studies have provided a link between translation factor activity,
cellular senescence and the expression of a number of oncogenes
(Sonenberg 1993; Anand et al, 2002; Zimmer et al, 2002).
Abnormal expression of translation factors such as EF-1 was
shown to have dramatic effects on cellular growth, including
transformation and tumorigenesis. We previously reported the
clinical significance of EF-1 gamma, and overexpression of EF-1
gamma mRNA was correlated with the aggressiveness of gastric
and oesophageal carcinomas (Mimori et al, 1995, 1996). Further-
more, elevated levels of EF-1 alpha and EF-1 gamma were also
found in cancers of the pancreas, colon, breast, lung, prostate and
stomach relative to normal tissues (Chi et al, 1992; Grant et al,
1992; Lew et al, 1992; Ender et al, 1993; Mathur et al, 1998; Su et al,
1998).
However, to the authors’ knowledge, there has been no
information on the clinical significance of EF-1 delta mRNA
expression in malignant tumours, such as oesophageal carcinoma.
Oesophageal carcinoma has proven to be one of the most difficult
malignancies to cure, and the prognosis for these patients has been
extremely poor (Roth et al, 1997). In contrast, long-term survival
was recognised in some patients who underwent a curative
operation, and it is therefore very important for surgeons and
gastroenterologists to identify effective markers for postoperative
prognosis. Consequently, we quantitated the expression of EF-1
delta in malignant and benign oesophageal tissues and investigated
whether these levels were associated with clinicopathologic
parameters and the prognosis in cases of oesophageal carcinoma.
MATERIALS AND METHODS
Patients and sample collection
Elongation factor-1 delta mRNA expression levels were investi-
gated in a series of 52 oesophageal carcinoma specimens from
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ypatients who underwent curative surgery at the Medical Institute of
Bioregulation Hospital, Kyushu University and Saitama Cancer
Center. All 52 patients were clearly identified based on clinico-
pathologic findings. No patients received chemotherapy or radio-
therapy prior to the operation. The patients included 47 males and
five females. Patient ages ranged from 40 to 82 years with a median
age of 63 years. In all, 10 tumours were well differentiated, 27 were
moderately differentiated, and eight were poorly differentiated
squamous cell carcinomas. Other types of carcinomas included
basal cell carcinoma (n¼3), adenocarcinoma (n¼2) and small-
cell carcinoma (n¼2). The depth of tumour invasion was as
follows: five involving the submucosa, nine involving the
muscularis propria and 38 in the adventitia or deeper. Patients
with lymph node metastases were classified into two groups: the
nonmetastatic group (n¼12) and the metastatic group (n¼40).
Carcinoma specimens were obtained from the tumour edge,
avoiding the necrotic centre, and corresponding distant normal
mucosa specimens were also obtained at least 5cm away from the
tumour edge by sharply dissecting the mucosa off the muscularis
propria. All specimens were immediately frozen in liquid nitrogen
and kept at  801C until the extraction of RNA. Written informed
consent was obtained from all patients.
Total RNA extraction
Frozen tissue specimens or cultured cells in a state of subcon-
fluency (human oesophageal cancer cell line KYSE30) were
homogenised in guanidinium thiocyanate, and total RNA was
obtained by ultracentrifugation through a cesium chloride cushion
as described previously (Mori et al, 1993; Yoshinaga et al, 2003).
KYSE30 was kindly provided by Dr Shimada (First Department of
Surgery, Faculty of Medicine, Kyoto University, Kyoto, Japan).
Real-time quantitative reverse transcription–polymerase
chain reaction (RT–PCR)
The cDNA was synthesised from 8.0mg of total RNA as described
previously (Inoue et al, 1995; Yamashita et al, 2001). Two gene-
specific oligonucleotide primers were designed:
sense EF-1 delta, 50-CCCGCGTCCGCCGATTCCTC-30;
antisense EF-1 delta, 50 CGCTGGCGCCGTTCTCCTG-30;
sense glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
50-TTGGTATCGTGGAAGGACTCA-30;
antisense GAPDH, 50-TGTCATCATATTTGGCAGGTT-30.
These primers spanned more than two exons to avoid
amplification of any contaminating DNA.
Real-time monitoring of PCR reactions was performed using the
LightCyclert system (Roche Applied Science, Indianapolis, IN,
USA), and SYBR green I dye (Roche Diagnostics), which binds
preferentially to double-stranded DNA, according to the manu-
facturer’s instructions. Fluorescent signals are proportional to the
concentration of the product and are measured at the end of each
cycle, rather than after a fixed number of cycles (Buckhaults et al,
2001). The higher the starting quantity of template, the earlier the
attainment of the threshold cycle, which is defined as the fractional
cycle number at which fluorescence passes a fixed threshold above
baseline (Bieche et al, 1998, 1999).
For cDNAs of the 52 paired oesophageal samples (cancerous
tissues and corresponding normal counterparts), the PCR reaction
was carried out on the Light Cycler system. For each run, a master
mixture, containing 1ml of cDNA, 2ml of LC DNA Master SYBR
Green I mix, 50ng of primers and 2.4mlo f2 5 m M MgCl2, was
prepared on ice. The final volume was adjusted to 20ml with water.
After the reaction mixture was loaded into the glass capillary tube,
the cycling conditions were carried out as follows: initial
denaturation at 951C for 10min, followed by 40 cycles of
denaturation at 951C for 10s, annealing at 621C (601C for GAPDH)
for 10s and extension at 721C for 10s. The temperature transition
rate was set at 201Cs
 1.
For distinguishing specific from nonspecific products and
primer dimers, a melting curve was obtained after amplification
by holding the temperature at 681C for 30s, and then gradually
increasing the temperature to 951C at a rate of 0.21Cs
 1.N o
amplification of nonspecific products was observed. To verify the
melting curve results, each representative sample of the PCR
products was run on 1.5% agarose gels, and a single PCR product
of the size predicted from the cDNA was confirmed.
We determined the levels of EF-1 delta and GAPDH mRNA
expression by comparisons with cDNA from the human oesopha-
geal cancer cell line KYSE30. After proportional baseline adjust-
ment, the fit point method was employed to determine the cycle in
which the log-linear signal was distinguished from the baseline,
and that cycle number (threshold cycle) was used as a crossing-
point value. The standard curve was produced by measuring the
crossing point of each standard value (four-fold serially diluted
cDNAs of KYSE30), and plotting them against the logarithmic
value of concentrations. The standard curve samples were included
in each run. The concentrations of each sample were then
calculated by plotting their crossing points against the standard
curve. All calculated concentrations are relative to the concentra-
tion of the cDNA of KYSE30, and the amount of target molecule
was then divided by the amount of the endogenous reference
(GAPDH), to obtain normalised EF-1 delta expression (Bieche et al,
1999). Each assay was performed at least twice to verify the results,
and the mean mRNA expression was used for analysis.
Statistical analysis
The median follow-up time for the 12 living patients was 8.0 years
(range: 5.1–11.4 years). Overall and cause-specific survival rates
were calculated actuarially according to the Kaplan–Meier method
(Kaplan and Meier, 1958), and were measured from the day of
surgery. Differences between groups were estimated using the w
2
test, the Student’s t test, and the log-rank test (Mantel, 1966). A
probability level of 0.05 was chosen for statistical significance.
Statistical analysis was performed with the SPSS software package
(version 6.1; SPSS, Inc., Chicago, IL, USA).
RESULTS
With regard to EF-1 delta mRNA expression in clinical samples, 38
of 52 patients (73%) showed a higher expression level of EF-1 delta
mRNA in cancerous tissues in comparison with noncancerous
tissues by real-time quantitative RT–PCR. The mean expression
level of EF-1 delta mRNA in tumour tissues, 0.25070.200
(mean7standard deviation (s.d.)), was significantly higher than
0.17870.151 in the corresponding normal tissues (Po0.01,
Figure 1). The median expression levels of EF-1 delta mRNA in
tumour tissues and normal tissues were 0.198 and 0.151,
respectively. In the current study, the patients with values less
than the median expression level (0.198) in tumour tissues were
considered to be in the low expression group (n¼26), whereas
those with values X0.198 were considered to be in the high
expression group (n¼26). Table 1 shows the clinicopathologic
data and EF-1 delta mRNA expression in the tumour specimens
from 52 patients with oesophageal carcinoma. The incidence of
lymph node metastasis in the high expression group (24 of 26,
92%) was significantly higher (P¼0.032) than that in the low
expression group (16 of 26, 62%). Moreover, the incidence of
advanced stages (according to the International Union Against
Cancer 1997 TNM classification system) in the high expression
group (20 of 26, 77%) was significantly higher (P¼0.023) than that
in the low expression group (12 of 26, 46%).
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analysis. A total of 27 patients died of oesophageal carcinoma, and
the remaining 13 patients died without any sign of clinical
recurrence (such as pneumonia and cerebrovascular diseases). The
5-year actuarial overall survival rates in patients with higher EF-1
mRNA levels and those with lower EF-1 mRNA levels were 19 and
42%, respectively. The difference between these two groups was
not statistically significant (P¼0.065). On the other hand, the 5-
year actuarial cause-specific survival rates were 23% for patients
with high EF-1 delta mRNA levels and 54% for those with low EF-1
delta mRNA levels (Figure 2), and this was significantly different
(P¼0.046).
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Figure 1 Elongation factor-1 delta expression in cancerous and
noncancerous oesophageal tissues. The horizontal lines indicate the means.
Cancer tissues showed significantly higher EF-1 delta mRNA expression
levels as compared to noncancerous tissues (Po0.01). The P-value was
calculated by the Student’s t-test.
Table 1 Clinicopathologic data and elongation factor-1 delta mRNa
expression in the tumour specimens of 52 patients with oesophageal
carcinoma
a
High expression
b Low expression
b
Variable n¼26 n¼26 P-value
Age 63.979.4 59.378.6 0.069
Gender (male)
Male 25 22 0.158
Female 1 4
Histological grade
a
Well 4 6 0.901
Moderately 14 13
Poorly 4 4
Others 4 3
Depth of invasion
Submucosa 1 4 0.525
Muscularis propria 4 5
Adventitia 21 17
Lymph node metastasis
Absent 3 9 0.032
d
Present 24 16
Lymphatic permeation
Absent 0 3 0.089
Present 26 23
Venous permeation
Absent 3 7 0.159
Present 23 19
Clinical stage
c
I, II 6 14 0.023
d
II, IV 20 12
aThis analysis included 45 squamous cell carcinomas and others including basal cell
carcinoma (n¼3), adenocarcinoma (n¼2) and small-cell carcinoma (n¼2).
bLow
and high groups were determined by a median value of elongation factor-1 delta
mRNA (0.198).
cAccording to the International Union Against Cancer 1997 TNM
classification system.
dStatistically significant.
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Figure 2 Actuarial cause-specific survival in patients with oesophageal carcinoma according to the level of EF-1 mRNA expression.
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The results of the current study indicated that EF-1 delta mRNA
overexpression in cancerous compared to noncancerous tissue is
commonly observed in patients with oesophageal carcinoma.
Moreover, the higher mRNA expression of EF-1 delta was
significantly associated with lymph node metastases and advanced
disease stages. Similar findings have also been reported in gastric
and colorectal cancer patients with a higher expression of EF-1
gamma (Chi et al, 1992; Mimori et al, 1995). We have also
demonstrated that oesophageal cancer patients with EF-1 gamma
overexpression disclosed severe lymph node metastases and many
of these patients were found to be in the most advanced stages
(Mimori et al, 1996).
The current study also indicated that a higher expression of EF-1
delta mRNA was correlated with poorer prognosis for patients with
oesophageal carcinoma. With regard to EF-1 delta expression in
cancers, Kolettas et al (1998) indicated that EF-1 delta was more
highly expressed in cDNA from the original cancer cell population
than in normal cells by Southern-plaque hybridisation. Shuda et al
(2000) found that the mRNA expression of EF-1 delta was
upregulated along with the histological grading (from well,
moderately, to poorly differentiated) in hepatocellular carcinoma.
The higher expression of EF-1 delta in the tumours suggested that
malignant transformation in vivo requires an increase in transla-
tion factor mRNA and protein synthesis for entry into and
transition through the cell cycle (Kolettas et al, 1998). Similarly,
others have indicated that EF-1 alpha and EF-1 gamma were highly
expressed in certain tumours including colon, lung, gastric,
pancreatic and breast tumours, relative to normal adjacent tissue
(Chi et al, 1992; Grant et al, 1992; Lew et al, 1992; Ender et al, 1993;
Mathur et al, 1998; Su et al, 1998). These results suggest that
alteration in the expression of EF-1, including EF-1 delta,
contribute to cell transformation and cancer development.
More recent reports have indicated that EF-1 delta can function
as a proto-oncogene when overexpressed (Joseph et al, 2002; Lei
et al, 2002). Joseph et al (2002) indicated that overexpression of
EF-1 delta protein by transfection was oncogenic in NIH3T3 cells,
as evidenced by the appearance of transformed foci exhibiting
anchorage-independent growth and the potential to grow as
tumours in nude mice. They also demonstrated that cell
transformation and tumorigenesis induced by cadmium are due,
at least in part, to the overexpression of EF-1 delta. Lei et al (2002)
found that blocking EF-1 delta with antisense mRNA resulted in a
significant reversal of its oncogenic potential. These results suggest
that EF-1 delta may function as a potential proto-oncogene when
overexpressed. Therefore, EF-1 delta may be used as a potential
therapeutic target or as a risk factor for carcinogenesis in tumours
that exhibit its overexpression.
Elongation factor-1 delta may have other actions, such as effects
on chemotherapy and ionising radiation (Jung et al, 1994; Sinha
et al, 2000). Sinha et al (2000) indicated that human EF-1 delta was
overexpressed in melanoma cell lines exhibiting chemoresistance
towards antineoplastic drugs, such as vindesine, cisplatin, fotems-
tine and etoposide. They suggested that the development of
chemoresistance towards anti-neoplastic drugs in melanoma cell
lines could be the results of a changed functionality of the general
translation machinery. With regard to ionising radiation, Jung et al
(1994) indicated that EF-1 delta was a radiation-inducible gene and
might participate in the G2-M cell cycle checkpoint. Further
functional studies (e.g., proliferation assays, transfection experi-
ments) should be undertaken to clarify the role of EF-1 delta
mRNA in chemoresistance and radiation-inducible gene expres-
sion.
In the current study, 38 of 52 oesophageal carcinoma patients
(73%) showed overexpression of EF-1, while the remaining 14
patients (27%) did not exhibit an overexpression of EF-1. These
results suggest that the etiological factors or the molecular
mechanisms responsible for oesophageal carcinogenesis may be
different for those tumour samples overexpressing EF-1 delta
compared to those not overexpressing EF-1 delta. We have
previously indicated that loss of fragile histidine triad (Fhit)
expression may be an early event in the development of human
oesophageal carcinoma and patients who were both heavy users of
tobacco and alcohol showed a significantly higher frequency of
loss of Fhit expression than those who were light users (Mori et al,
2000). Since EF-1 delta has been proven to be a cadmium-
responsive proto-oncogene (Joseph et al, 2002), the potential
etiological factors, such as exposure to certain chemical carcino-
gens and lifestyle (smoking and alcoholism), may also affect the
expression of EF-1 delta in patients with oesophageal carcinoma,
as was observed with Fhit expression. However, the precise
mechanisms of EF-1 delta overexpression in oesophageal carcino-
ma are uncertain. The amplification of the genomic locus of EF-1
delta, located on chromosome 8q24.3, or the promotion of gene
transcription may explain EF-1 delta overexpression. Further
studies are required to elucidate the possible mechanisms of EF-1
delta overexpression in oesophageal carcinoma.
In conclusion, our results indicated that EF-1 mRNA was
overexpressed in oesophageal carcinoma tissues, and higher
expression levels were correlated with lymph node metastasis,
advanced disease stages and poor prognosis. These findings
suggest a possible role for EF-1 delta expression as an additional
diagnostic and prognostic biomarker for oesophageal carcinoma.
Furthermore, understanding the biological function of EF-1 delta
expression in oesophageal tissue may help to delineate its role in
oesophageal physiology and the pathology of oesophageal
carcinoma.
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